DARE vs. VTGN, REPH, ABEO, CAPR, TRVI, OGI, PBYI, RPTX, RIGL, and GALT
Should you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Vistagen Therapeutics (VTGN), Recro Pharma (REPH), Abeona Therapeutics (ABEO), Capricor Therapeutics (CAPR), Trevi Therapeutics (TRVI), Organigram (OGI), Puma Biotechnology (PBYI), Repare Therapeutics (RPTX), Rigel Pharmaceuticals (RIGL), and Galectin Therapeutics (GALT). These companies are all part of the "medical" sector.
Daré Bioscience (NASDAQ:DARE) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends.
Daré Bioscience has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
Daré Bioscience has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -3,073.51%. Vistagen Therapeutics' return on equity of -72.10% beat Daré Bioscience's return on equity.
Daré Bioscience has higher revenue and earnings than Vistagen Therapeutics.
Daré Bioscience received 73 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. Likewise, 73.29% of users gave Daré Bioscience an outperform vote while only 72.24% of users gave Vistagen Therapeutics an outperform vote.
Daré Bioscience presently has a consensus target price of $4.50, indicating a potential upside of 765.38%. Vistagen Therapeutics has a consensus target price of $19.00, indicating a potential upside of 401.32%. Given Daré Bioscience's higher possible upside, research analysts plainly believe Daré Bioscience is more favorable than Vistagen Therapeutics.
6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are held by institutional investors. 4.0% of Daré Bioscience shares are held by company insiders. Comparatively, 1.0% of Vistagen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Vistagen Therapeutics had 2 more articles in the media than Daré Bioscience. MarketBeat recorded 2 mentions for Vistagen Therapeutics and 0 mentions for Daré Bioscience. Vistagen Therapeutics' average media sentiment score of 0.77 beat Daré Bioscience's score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.
Summary
Daré Bioscience and Vistagen Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Daré Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Daré Bioscience Competitors List
Related Companies and Tools
